2 November 2017 - - New York, New York-based biopharmaceutical company Bristol-Myers Squibb (NYSE: BMY) is the founding sponsor of Cambridge, Massachusetts-based shared lab facilities network BioLabs' newest location, BioLabs@NYULangone, launched in partnership with NYU Langone Health, the companies said.
As part of the agreement, for each year of active sponsorship, Bristol-Myers Squibb can nominate up to three innovative life-sciences and biotech startup companies per year to take up residence in BioLabs' facilities at 180 Varick Street in Manhattan.
The nomination process will launch in early 2018.
A Golden Ticket represents one underwritten bench space per year for one scientist at BioLabs, and a priority spot on the waiting list. The Golden Ticket also promotes collaboration among sponsors and the start-up companies.
The program provides sponsors with early access to potentially transformational targets and technology, and the start-ups with the mentorship of their sponsor teams.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV).
BioLabs is a membership-based network of shared lab facilities located in key biotech innovation clusters in the US, designed exclusively for high-potential, early-stage life science companies. It offers coworking environments that pair premium, fully equipped and supported lab and office space with access to capital and industry partners. Companies can start with a single bench, and scale up as they grow.
BioLabs' founding site is in Kendall Square, Cambridge, Massachusetts, with additional locations in North Carolina; San Diego, California; and opening in New York, New York. Partner sites include LabCentral in Kendall Square, and QB3@953 in San Francisco, California.